Marizyme, Inc. (MRZM)

OTCMKTS: MRZM · Delayed Price · USD
0.0533
0.00 (0.00%)
May 21, 2024, 11:05 AM EDT - Market closed
Market Cap 7.02M
Revenue (ttm) 549,691
Net Income (ttm) -69.02M
Shares Out 131.79M
EPS (ttm) -1.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open 0.0930
Previous Close 0.0533
Day's Range n/a
52-Week Range 0.0500 - 0.4100
Beta 0.21
Analysts n/a
Price Target n/a
Earnings Date n/a

About MRZM

Marizyme, Inc., a multi-technology biomedical company, develops and commercializes medical technologies to enhances patients health. It's product portfolio includes DuraGraft, a first-in-class, De Novo granted and CE marked intra-operative vascular graft storage and flushing solution used during coronary artery bypass graft (CABG) surgeries; MATLOC, a point-of-care, lab-on-chip technology platform, developed for quantitative chronic kidney disease assessment; and Krillase, a protein enzyme that acts to break protein bonds and has applications i... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 13
Stock Exchange OTCMKTS
Ticker Symbol MRZM
Full Company Profile

Financial Performance

In 2023, Marizyme's revenue was $645,810, an increase of 176.60% compared to the previous year's $233,485. Losses were -$65.35 million, 5.10% more than in 2022.

Financial Statements

News

Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™

JUPITER, FL, April 16, 2024 (GLOBE NEWSWIRE) -- via  NewMediaWire  -- Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, ...

2 months ago - GlobeNewsWire

Marizyme CEO Delivers Business Update

JUPITER, FL, Oct. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - Marizyme, Inc. ("Marizyme" or the "Company") (OTCQB: MRZM), today provided the following business update to the stockholders and the i...

8 months ago - GlobeNewsWire

Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft™

DuraGraft is the first and only FDA cleared medical device for use as an intra-operative vascular conduit storage and flushing solution used during CABG surgeries

9 months ago - GlobeNewsWire

Marizyme Announces IP Developments for DuraGraft® and Its Pipeline Products

JUPITER, FL, May 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Marizyme, Inc. ("Marizyme" or the "Company") (OTCQB: MRZM), a multi-technology biomedical company focused on the accelerated developmen...

1 year ago - GlobeNewsWire

Marizyme Announces Allowance of Patent Application for Flagship Product DuraGraft by United States Patent and Trademark Office

Jupiter, FL, Jan. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme, Inc. (“Marizyme” or the “Company”) (OTCQB: MRZM) is pleased to announce that the United States Patent and Trademark Office ...

2 years ago - GlobeNewsWire

Marizyme Announces the Closing of My Health Logic Acquisition Along With Initial Financing

JUPITER, Fla., Dec. 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme Inc. (“Marizyme” or the “Company”) (OTCQB:MRZM), is pleased to announce the closing of its acquisition of My Health Logic ...

2 years ago - GlobeNewsWire

Marizyme Inc. Announces Results of GOAL Study Presented at 7th Annual International Coronary Congress

JUPITER, FL, Dec. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Marizyme Inc. (MRZM), a biotechnology company engaged in the development and commercialization of products to prevent, treat and diagn...

2 years ago - GlobeNewsWire

Marizyme Announces Expansion of Patent Portfolio Into Several Key Territories

Jupiter, FL, Dec. 03, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire --  Marizyme Inc. (MRZM), a biotechnology company engaged in the development and commercialization of advanced healthcare products to p...

2 years ago - GlobeNewsWire

Marizyme is Pleased to Announce the Appointment of David Barthel as CEO

JUPITER, Fla., Nov. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme Inc. (“Marizyme” or the “Company”) (OTCQB:MRZM), is pleased to announce the hiring of Mr. David Barthel as the Chief Execu...

2 years ago - GlobeNewsWire

Marizyme, Inc. Issues Letter to Shareholders

JUPITER, Fla., March 31, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB: MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in ti...

3 years ago - PRNewsWire

Marizyme Announces New Distribution and Channel Partnership for Chilean Market with Abdera

JUPITER, Fla., March 4, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tiss...

3 years ago - PRNewsWire

Marizyme, Inc. Strengthens Senior Management Team with Two Appointments: Roger Schaller EVP, Commercial Operations and Amy Chandler, EVP, Regulatory Affairs and Quality Management Systems

JUPITER, Fla., Feb. 1, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissu...

3 years ago - PRNewsWire

Marizyme Announces Approval for DuraGraft® in India

JUPITER, Fla., Jan. 14, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tiss...

3 years ago - PRNewsWire

Marizyme Announces the Use of DuraGraft® as the Standard-of-Care in Patients Undergoing Coronary Artery Bypass Surgery (CABG) at Vienna Heart Center North Floridsdorf

JUPITER, Fla., Jan. 11, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB: MRZM), a global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, or...

3 years ago - PRNewsWire

Marizyme, Inc. to Present at Biotech Showcase 2021 During the J.P. Morgan Healthcare Conference Biotech Showcase Digital, BIO @ JPM During "J.P.

JUPITER, Fla., Jan. 7, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissu...

3 years ago - PRNewsWire